Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries

Bone Marrow Transplantation volume 55, pages 698–707 (2020)Cite this article

Subjects

A Correction to this article was published on 15 October 2019

This article has been updated

Abstract

Health care costs attributed to biologics have increased exponentially in the recent years, thus biosimilars offer a possible solution to limit costs while maintaining safety and efficacy. Reducing expenditure is vital to health care especially in developing countries where affordability and access to health care is a major challenge. We discuss the opportunities and the challenges of biosimilars in the field of hematopoietic cell transplantation (HCT) in low- and lower-middle income countries. Developing countries can potentially invest in the forecasted costs reduction by utilizing biosimilars. This can be used to decrease the costs of procedures such as HCT, which is a rapidly growing field in many developing regions. The introduction of biosimilars in the developing regions faces many challenges which include, but are not limited to: legal and regulatory issues, lack of research infrastructure, and the presence of educational barriers. Thus, collaborative efforts are needed to ensure an effective and safe introduction of biosimilars into low- and lower-middle income countries.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Change history

References

  1. Patel D, Gillis C, Naggar J, Mistry A, Mantzoros C. The rise of biosimilars: how they got here and where they are going. Metabolism. 2017;75:45–53.

    CAS  PubMed  Google Scholar 

  2. Weise M, Bielsky M, De Smet K, Ehmann F, Ekman N, Giezen T, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.

    CAS  PubMed  Google Scholar 

  3. Loo J. Industry surveys: biotechnology. Standard & Poor’s. New York; 2014.

  4. Gascon P. The evolving role of biosimilars in haematology–oncology: a practical perspective. Ther Adv Hematol. 2015;6:267–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Hirsch B, Lyman G. Biosimilars: a cure to the U.S. health care cost conundrum? Blood Rev. 2014;28:263–8.

    PubMed  Google Scholar 

  6. Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Glob Oncol. 2017;3:596–610.

    PubMed  PubMed Central  Google Scholar 

  7. Blackstone E, Fuhr J. The economics of biosimilars. Am Health Drug Benefits 2013;6:469–78.

    PubMed  PubMed Central  Google Scholar 

  8. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Cancer Netw. 2011;9:S1–S22.

    CAS  Google Scholar 

  9. Khera N, Zeliadt S, Lee S. Economics of hematopoietic cell transplantation. Blood. 2012;120:1545–51.

    CAS  PubMed  Google Scholar 

  10. Khera N, Emmert A, Storer B, Sandmaier B, Alyea E, Lee S. Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens. Oncologist. 2014;19:639–44.

    PubMed  PubMed Central  Google Scholar 

  11. Hashmi S, Srivastava A, Rasheed W, Adil S, Wu T, Jagasia M, et al. Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematol Oncol Stem Cell Ther 2017;10:167–72.

    PubMed  Google Scholar 

  12. Gratwohl A, Pasquini M, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91–e100.

    PubMed  Google Scholar 

  13. Baldomero H, Aljurf M, Zaidi S, Hashmi S, Ghavamzadeh A, Elhaddad A, et al. Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplant. 2019;54:402–17.

  14. Aljurf M, Nassar A, Hamidieh A, Elhaddad A, Hamladji R, Bazarbachi A, et al. Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011–2012: a comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT). Hematol Oncol Stem Cell Ther. 2015;8:167–75.

    PubMed  Google Scholar 

  15. Gratwohl A, Baldomero H, Aljurf M, Pasquini M, Bouzas L, Yoshimi A, et al. Hematopoietic stem cell transplantation a global perspective. JAMA. 2010;303:1617–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Gale R, Seber A, Bonfim C, Pasquini M. Haematopoietic cell transplants in Latin America. Bone Marrow Transplant. 2016;51:898–905.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Bazarbachi A, Labopin M, Ghavamzadeh A, Giebel S, Al-Zahrani H, Ladeb S, et al. Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers. Bone Marrow Transplant. 2013;48:1065–9.

    CAS  PubMed  Google Scholar 

  18. Abdel-Rahman F, Hussein A, Rihani R, Hlalah O, El Taani H, Sharma S, et al. Bone marrow and stem cell transplantation at King Hussein cancer center. Bone Marrow Transplant. 2008;402:S89–S91.

    Google Scholar 

  19. Jaime-Perez J, Heredia-Salazar A, Cantu-Rodriguez O, Gutierrez-Aguirre H, Villarreal-Villarreal C, Mancias-Guerra C, et al. Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in Northeast Mexico. Oncologist. 2015;20:386–92.

    PubMed  PubMed Central  Google Scholar 

  20. Sharma SK, Choudhary D, Gupta N, Dhamija M, Khandelwal V, Kharya G, et al. Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis. 2014;6:e2014046.

    PubMed  PubMed Central  Google Scholar 

  21. Lyman G, Zon R, Harvey R, Schilsky R. Rationale, opportunities, and reality of biosimilar medications. New Engl J Med. 2018;378:2036–44.

    PubMed  Google Scholar 

  22. Biosimilar Product Information. Fda.gov. https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580432.htm (2018).

  23. Centrally authorised biosimilar medicines| European Medicines Agency. Ema.europa.eu. https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar (2018).

  24. Lisenko K, Baertsch MA, Meiser R, Pavel P, Bruckner T, Kriegsmann M, et al. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma. Transfusion. 2017;57:2359–65. Oct

    CAS  PubMed  Google Scholar 

  25. Sivgin S, Karakus E, Keklik M, Zararsiz G, Solmaz M, Kaynar L, et al. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34+ peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors. Transfus Apher Sci. 2016;54:410–5.

    PubMed  Google Scholar 

  26. Sivgin S, Karakus E, Kaynar L, Kurnaz F, Pala C, Keklik M, et al. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. Transfus Apher Sci. 2013;48:315–20.

    PubMed  Google Scholar 

  27. Corbin M, Peyton-Thomas B, Selby C, Bozeman A, Leary C, Devarakonda S, et al. Efficacy of a tbo-filgrastim protocol for stem cell engraftment in autologous stem cell transplant. Biol Blood Marrow Transplant. 2017;23:S417–S418.

    Google Scholar 

  28. Harada K, Yamada Y, Konishi T, Nagata A, Takezaki T, Kaito S, et al. Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2016;104:709–19.

    CAS  PubMed  Google Scholar 

  29. Ianotto J, Ngo Sack F, Couturier M, Tempescul A, Mugnier N, Delepine P, et al. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery. Leuk Lymphoma. 2013;55:74–77.

    PubMed  Google Scholar 

  30. León-González M, León-Peña AA, Vallejo-VIllalobos MF, Núñez-Cortés AK, Ruiz-Argüelles A, Ruiz-Argüelles GJ. Mexican biosimilar filgrastim for autologous hematopoietic stem cell mobilization and transplantation. Rev Investig Clin. 2016;68:181–3.

    Google Scholar 

  31. Halim L, Márquez M, Maas-Bakker R, Castañeda-Hernández G, Jiskoot W, Schellekens H. Quality comparison of biosimilar and copy filgrastim products with the innovator product. Pharm Res. 2018;35:1–12.

  32. Najjar R, Sharma S, Farraj R, Muffarrej D, Haroun A, Hashem H, et al. Comparable efficacy of peripheral stem cell mobilization using biosimilar Filgrastim Nivestim® to original Neupogen® in healthy donors. Bone Marrow Transplantation: 2019 53:766.

  33. U.S. Food and Drug Administration. Rituximab; Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf. Accessed 18 Nov 2018.

  34. Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93:578–85. May

    CAS  PubMed  Google Scholar 

  35. Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122:1510–7. Aug

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756–62. Jul

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119:6145–54. Jun

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Hodge G, Hodge S, Chambers D, Reynolds PN, Holmes M. Bronchiolitis obliterans syndrome is associated with absence of suppression of peripheral blood Th1 proinflammatory cytokines. Transplantation. 2009;88:211–8. Jul

    PubMed  Google Scholar 

  39. Yalniz FF, Hefazi M, McCullough K, Litzow MR, Hogan WJ, Wolf R, et al. Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23:1478–84. Sep

    CAS  PubMed  Google Scholar 

  40. De Jong CN, Saes L, Klerk CPW, Van der Klift M, Cornelissen JJ, Broers AEC. Etanercept for steroid-refractory acute graft-versus-host disease: a single center experience. PLoS ONE. 2017;12:e0187184. Oct

    PubMed  PubMed Central  Google Scholar 

  41. Park JH, Lee HJ, Kim SR, Song GW, Lee SK, Park SY, et al. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Korean J Intern Med. 2014;29:630–6.

    PubMed  PubMed Central  Google Scholar 

  42. Yanik G, Hellerstedt B, Custer J, et al. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:395–400.

    CAS  PubMed  Google Scholar 

  43. Fullmer JJ, Fan LL, Dishop MK, Rodgers C, Krance R. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics. 2005;116:767–70.

    PubMed  Google Scholar 

  44. Eleryan MG, Akhiyat S, Rengifo-pardo M, Ehrlich A. Biosimilars: potential implications for clinicians. Clin Cosmet Investig Dermatol. 2016; 9:135–42.

  45. Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Santa Monica, CA: RAND; 2017.

  46. Peters DH, Garg A, Bloom G, Walker DG, Brieger WR, Rahman MH. Poverty and access to health care in developing countries. Ann N Y Acad Sci 2008;1136:161–71.

    PubMed  Google Scholar 

  47. O’Donnell O. Access to health care in developing countries: breaking down demand side barriers. Cad Saude Publica. 2007;23:2820–34.

    PubMed  Google Scholar 

  48. Qureshi ZP, Magwood JS, Singh S, et al. Rituximab and biosimilars: equivalence and reciprocity. Biosimilars. 2013;2013:19–25.

  49. What’s next for biosimilars in emerging markets? McKinsey & Company; 2019. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/whats-next-for-biosimilars-in-emerging-markets.

  50. Rägo L, Sillo H, ‘t Hoen E, Zweygarth M. Regulatory framework for access to safe, effective quality medicines. Antivir Ther. 2014;19:69–77.

    PubMed  Google Scholar 

  51. Pezzola A, Sweet CM. Global pharmaceutical regulation: the challenge of integration for developing states. Glob Health 2016;85:1–18.

    Google Scholar 

  52. Krishnan A, Mody R, Malhotra H. Global regulatory landscape of biosimilars: emerging and established market perspectives. Biosimilars. 2015; 5:19–32.

  53. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft guidance). US Food and Drug Administration; 2015http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.

  54. Biosimilars in the EU: information guide for healthcare professionals. European Medicines Agency and the European Commission; 2017https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf.

  55. Chauhan M, Malik S. Regulatory guidelines for approval of biosimilars In India, Europe, Brazil And China: a comprehensive overview. Int J Pharm Pharm Sci. 2016;8:7.

    Google Scholar 

  56. Biosimilars in Brazil. Pinheironeto.com.br. 2019http://www.pinheironeto.com.br/Documents/Artigos/Biosimilars_Brazil_JAN2017.pdf.

  57. Guidance for registration of biosimilars. Jordan Food & Drug Administration; 2014 http://old.jfda.jo/Download/News/239_530.pdf.

  58. Guideline for registration of biosimilar products. Central Administration for Pharmaceutical Affairs: Ministry of health. http://www.eda.mohp.gov.eg/Files/304_guidelines%20after%20correction.pdf.

  59. Guideline on biosimilar product: quality considerations. Saudi Arabia Food & Drug Administration; 2017 https://www.sfda.gov.sa/ar/drug/resources/DocLib2/Guideline-on-biosimilar-products.pdf.

  60. Guidelines on similar biologic: regulatory requirements for marketing authorization in India. http://cdsco.nic.in/writereaddata/Proposed%20Guidelines%20for%20Similar%20Biologic%202016.pdf.

  61. Guidelines for ensuring the quality, safety and efficacy of biosimilar products. Japanese Pharmaceuticals and Medical Devices Agency. https://www.pmda.go.jp/files/000206248.pdf.

  62. Alhawassi T, Abuelizz H, Almetwazi M, Mahmoud M, Alghamdi A, Alruthia Y, et al. Advancing pharmaceuticals and patient safety in Saudi Arabia: a 2030 vision initiative. Saudi Pharm J. 2018;26:71–74.

    PubMed  Google Scholar 

  63. Cheraghali A. Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. DARU J Pharma Sci. 2012;20:1–4.

  64. Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77:671–7.

    PubMed  PubMed Central  Google Scholar 

  65. Surendiran A, Pradhan SC, Adithan C. Role of pharmacogenomics in drug discovery and development. Indian J Pharmacol. 2008;40:137–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol. 2014;133:16–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Amerson RM, Strang CW. Addressing the challenges of conducting research in developing countries. J Nurs Scholarsh. 2015;47:584–91. Nov

    PubMed  PubMed Central  Google Scholar 

  68. Jacobs I, Singh E, Sewell KL, et al. Patient attitudes and understanding about biosimilars: an international cross sectional survey. Patient Prefer Adherence. 2016;10:937–48.

    PubMed  PubMed Central  Google Scholar 

  69. Tomaszewski D. Biosimilar naming conventions: pharmacist perceptions and impact on confidence in dispensing biologics. J Manag Care Spec Pharm. 2016;22:919–26.

    PubMed  Google Scholar 

  70. Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33:2160–72.

    PubMed  Google Scholar 

  71. Cook J, McGrath M, Dixon M, Switchenko J, Harvey R, Pentz R. Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol. 2019;11:1–12.

  72. Farhat F, Othman A, el Karak F, Kattan J. Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region. SpringerPlus. 2016;5:2113.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Leadership of the CIBMTR’s Health Services and International Studies working committee.

Author information

Authors and Affiliations

  1. Department of Medicine, Houston Methodist Hospital, Houston, TX, USA

    Ibrahim N. Muhsen

  2. Hematology Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

    Shahrukh K. Hashmi, Walid Rasheed & Mahmoud Aljurf

  3. Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Shahrukh K. Hashmi

  4. Department of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany

    Dietger Niederwieser

  5. Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany

    Nicolaus Kroeger

  6. Division of Haemato-Oncology, Bart’s Health NHS Trust and Blizard Institute, Queen Mary University of London, London, UK

    Samir Agrawal

  7. Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI, USA

    Marcelo C. Pasquini, Wael Saber & Mary M. Horowitz

  8. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

    Yoshiko Atsuta

  9. Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA

    Karen K. Ballen

  10. Hospital Samaritano de, Sao Paulo, Brazil

    Adriana Seber

  11. Department of Medicine, Division of Hematology-Oncology and Blood and Marrow Transplantation program, Mayo Clinic, Jacksonville, FL, USA

    Mohamed A. Kharfan-Dabaja

  12. Keio University School of Medicine, Tokyo, Japan

    Shinichiro Okamoto

  13. Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA

    Nandita Khera

  14. Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA

    William A. Wood

  15. St George University Hospital, London, United Kingdom

    Mickey B. C. Koh

  16. Medical University of Graz, LKH-University, Klinikum Graz, Austria

    Hildegard Greinix

  17. Center for Hematopoietic Stem Cell Transplantation, Aichi Medical University Hospital, Nagakute, Japan

    Yoshihisa Kodera

  18. Department of Clinical Haematology, Royal Melbourne Hospital, Melbourne, VIC, Australia

    Jeff Szer

  19. University of Minnesota, Minneapolis, MN, USA

    Daniel Weisdorf

Authors
  1. Ibrahim N. Muhsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahrukh K. Hashmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dietger Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicolaus Kroeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samir Agrawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcelo C. Pasquini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshiko Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karen K. Ballen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Adriana Seber
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wael Saber
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mohamed A. Kharfan-Dabaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Walid Rasheed
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Nandita Khera
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. William A. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Mickey B. C. Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Hildegard Greinix
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yoshihisa Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Jeff Szer
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Mary M. Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Daniel Weisdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Mahmoud Aljurf
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

IM, MA, and SKH wrote the first draft of the paper. All authors vouch for the accuracy and contents of the paper. All authors approved the final version of the draft.

Corresponding author

Correspondence to Shahrukh K. Hashmi.

Ethics declarations

Conflict of interest

SKH: Honorarium: Mallinckrodt, Novartis, Janssen. Advisory board: Novartis, Janssen.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muhsen, I.N., Hashmi, S.K., Niederwieser, D. et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant 55, 698–707 (2020). https://doi.org/10.1038/s41409-019-0658-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0658-2

This article is cited by

Search

Advanced search

Quick links